Technical Analysis for RPRX - Royalty Pharma plc

Grade Last Price % Change Price Change
F 26.78 0.30% 0.08
RPRX closed up 0.3 percent on Thursday, September 28, 2023, on 74 percent of normal volume. The price action carved out a bearish shooting star candlestick pattern. That may indicate a downside reversal. Look for price to trade beneath the low of the shooting star for confirmation.

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Strong Down Down Down

Date Alert Name Type % Chg
Shooting Star Candlestick Bearish 0.00%
1,2,3 Retracement Bearish Bearish Swing Setup 0.00%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 0.00%
Calm After Storm Range Contraction 0.00%
Gapped Up Strength 0.30%
Oversold Stochastic Weakness 0.30%
1,2,3 Retracement Bearish Bearish Swing Setup 0.15%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 0.15%
Calm After Storm Range Contraction 0.15%
Up 3 Days in a Row Strength 0.15%

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
10 DMA Resistance about 10 hours ago
Rose Above 10 DMA about 10 hours ago
60 Minute Opening Range Breakout about 11 hours ago
Up 1% about 11 hours ago
Down 1% 1 day ago

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Royalty Pharma Plc provides drug development services. It operates as a funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and not-for-profits through small and mid-cap biotechnology companies to global pharmaceutical companies. The firm's portfolio includes royalties, including AbbVie and J&J's Imbruvica, Astellas and Pfizer's Xtandi, Biogen's Tysabri, Gilead's HIV franchise, Merck's Januvia, Novartis' Promacta, and Vertex's Kalydeco, Symdeko and Trikafta, and four development-stage product candidates. It focuses on acquiring royalty-generating products segment. The firm invests in biopharmaceutical products. The company was founded by Pablo Gerardo Legorreta in 1996 and is headquartered in New York, NY.
Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Pharmaceutical Pharmaceutical Products Drug Development HIV Biopharmaceutical Products

Is RPRX a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 43.6712
52 Week Low 25.92
Average Volume 2,042,913
200-Day Moving Average 33.66
50-Day Moving Average 29.44
20-Day Moving Average 28.14
10-Day Moving Average 27.04
Average True Range 0.62
RSI (14) 29.58
ADX 31.55
+DI 14.13
-DI 33.02
Chandelier Exit (Long, 3 ATRs) 29.00
Chandelier Exit (Short, 3 ATRs) 27.79
Upper Bollinger Bands 30.60
Lower Bollinger Band 25.68
Percent B (%b) 0.22
BandWidth 17.50
MACD Line -0.88
MACD Signal Line -0.77
MACD Histogram -0.1192
Fundamentals Value
Market Cap 9.8 Billion
Num Shares 366 Million
EPS -0.62
Price-to-Earnings (P/E) Ratio -43.12
Price-to-Sales 12.88
Price-to-Book 5.94
PEG Ratio -0.02
Dividend 0.60
Dividend Yield 2.24%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 27.43
Resistance 3 (R3) 27.45 27.27 27.32
Resistance 2 (R2) 27.27 27.10 27.25 27.28
Resistance 1 (R1) 27.02 27.00 27.15 27.00 27.25
Pivot Point 26.84 26.84 26.90 26.82 26.84
Support 1 (S1) 26.59 26.67 26.72 26.57 26.31
Support 2 (S2) 26.41 26.57 26.39 26.28
Support 3 (S3) 26.16 26.41 26.24
Support 4 (S4) 26.14